Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 12/20 | 0.46 |
| ▸ | MAPT | P10636 | 11/20 | 0.46 |
| ▸ | NPC1 | O15118 | 7/20 | 0.46 |
| ▸ | RAB9A | P51151 | 6/20 | 0.46 |
| ▸ | CASP3 | P42574 | 2/20 | 0.46 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.46 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.46 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.46 |
| ▸ | IKBKB | O14920 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.37 |
| ▸ | MEN1 | O00255 | 5/20 | 0.37 |
| ▸ | HPGD | P15428 | 4/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6176763 | 0.82 | ALDH1A1 (0.40) | KDM4EMAPTNPC1RAB9AIKBKB | |
| SCHEMBL3057874 | 0.81 | KDM4E (0.50) | KDM4EMAPTNPC1RAB9ACASP3 | |
| SCHEMBL12523234 | 0.80 | RAF1 (0.51) | KDM4EMAPTNPC1RAB9ACASP3 | |
| Hydrochloric Acid SCHEMBL10729329 | 0.77 | HSD17B10 (0.47) | KDM4EMAPTNPC1RAB9ACASP3 | |
| SCHEMBL19838115 | 0.76 | IKBKB (0.49) | KDM4EMAPTNPC1RAB9ACASP3 | |
| SCHEMBL7086159 | 0.74 | MEN1 (0.33) | KMT2AMEN1ALOX15L3MBTL1 | |
| SCHEMBL4168382 | 0.74 | KDM4E (0.44) | KDM4EMAPTNPC1RAB9ACASP3 | |
| SCHEMBL27643975 | 0.72 | MAPT (0.49) | KDM4EMAPTNPC1RAB9ACASP3 | |
| SCHEMBL4180494 | 0.72 | KDM4E (0.43) | KDM4EMAPTNPC1RAB9ACASP3 | |
| SCHEMBL4169616 | 0.72 | MAPT (0.43) | KDM4EMAPTNPC1RAB9ACASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100160371-A1 | INHIBITION OF P38 KINASE ACTIVITY BY ARYL UREAS | RANGES GERALD | 2010-06-24 | — | — | US | disclosed |
| EP-1163236-B1 | AROMATIC HETEROCYCLIC COMPOUNDS AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMA (US) | 2005-11-09 | — | — | EP | disclosed |
| EP-1019040-B1 | ARYL UREAS FOR THE TREATMENT OF INFLAMMATORY OR IMMUNOMODULATORY DISEASES | BAYER AG (US) | 2004-09-29 | — | — | EP | disclosed |
| US-6476023-B1 | Aromatic heterocyclic compounds as anti-inflammatory agents | BOEHRINGEN INGELHEIM PHARMACEUTICALS, INC. | 2002-11-05 | — | — | US | disclosed |
| US-20020103253-A1 | Inhibition of p38 kinase activity by aryl ureas | BAYER CORPORATION (US) | 2002-08-01 | — | — | US | disclosed |
| US-6344476-B1 | Inhibition of p38 kinase activity by aryl ureas | BAYER CORPORATION | 2002-02-05 | — | — | US | disclosed |
| EP-1163236-A1 | AROMATIC HETEROCYCLIC COMPOUNDS AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2001-12-19 | — | — | EP | disclosed |
| US-6297381-B1 | INHIBIT THE RELEASE OF INFLAMMATORY CYTOKINES SUCH AS INTERLEUKIN-1 AND TUMOR NECROSIS FACTOR, UREAS OR THIOUREAS SUBSTITUTED BY A PYRROLE OR THIOPHENE | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2001-10-02 | — | — | US | disclosed |
| EP-1019040-A4 | INHIBITION OF p38 KINASE ACTIVITY BY ARYL UREAS | BAYER AG (US) | 2000-10-04 | — | — | EP | disclosed |
| WO-2000055152-A1 | AROMATIC HETEROCYCLIC COMPOUNDS AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2000-09-21 | — | — | WO | disclosed |
| EP-1019040-A1 | INHIBITION OF p38 KINASE ACTIVITY BY ARYL UREAS | Bayer Corporation (US) | 2000-07-19 | — | — | EP | disclosed |
| WO-1998052558-A1 | INHIBITION OF p38 KINASE ACTIVITY BY ARYL UREAS | BAYER CORPORATION (US) | 1998-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103253-A1 | Inhibition of p38 kinase activity by aryl ureas | MAPK1, MAP3K1, MAP3K7 | KDM4E 2456/4885MAPT 638/4885NPC1 3093/4885 |
| US-20100160371-A1 | INHIBITION OF P38 KINASE ACTIVITY BY ARYL UREAS | MAPK1, MAP3K1, MAP3K7 | KDM4E 2456/4885MAPT 638/4885NPC1 3093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.